FDA Approves Nucleus Hybrid L24 Cochlear Implant System

Australian biotechnology company Cochlear Ltd revealed that it has secured approval from the US Food and Drug Administration to sell its Nucleus Hybrid L24 Cochlear Implant System in the American market.

According to Cochlear, the new implant will help improve hearing in patients who are able to hear low frequency sounds without the help of any hearing aid but suffer from hearing loss in high frequencies.

The device works by using electrical stimulation for high frequencies and acoustic amplification for low frequencies, the company said.

Stating that the device will provide new treatment options for people suffering from this type of hearing loss, FDA's Christy Foreman said, "Hearing loss greatly impacts the education, employment, and well-being of many Americans. This device may provide improved speech recognition for people with this kind of hearing loss, who have limited treatment options."


Source: Medindia